Brenda D. Jamerson, PharmD: Effect of Bupropion SR on Specific Symptom Clusters of Depression: Analysis of the 31-Item Hamilton Rating Scale for Depression

Name: Brenda D. Jamerson, PharmD: Effect of Bupropion SR on Specific Symptom Clusters of Depression: Analysis of the 31-Item Hamilton Rating Scale for Depression
SKU: 2991
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 37 No. 2 Articles Tags: alok-krishen, antidepressants, brenda-d-jamerson, chb, domains, jack-g-modell, jeremy-roberts, k-ranga-rama-krishnan, pharmd, principal-component-analysis, psychometrics, symptom-clusters

Description

Brenda D. Jamerson, PharmD: Effect of Bupropion SR on Specific Symptom Clusters of Depression: Analysis of the 31-Item Hamilton Rating Scale for Depression

Description

Brenda D. Jamerson, PharmD

EVIDENCE-BASED MEDICINE

Effect of Bupropion SR on Specific Symptom Clusters of Depression: Analysis of the 31-Item Hamilton Rating Scale for Depression

Brenda D. Jamerson, PharmD, K. Ranga Rama Krishnan, MB, ChB, Jeremy Roberts, MS, Alok Krishen, MSc, MS, and Jack G. Modell, MD

Depression Rating Scales – A Doctor’s Guide

Generalized Anxiety Disorder: Raising the Expectations of Treatment

New Goals in the Treatment of Depression: Moving Toward Recovery By Michael E. Thase, MD, and Philip T. Ninan, MD

Switching to Duloxetine Remits Ziprasidone – Edward C. Lauterbach

Brenda D. Jamerson, PharmD: Effect of Bupropion SR on Specific Symptom Clusters of Depression: Analysis of the 31-Item Hamilton Rating Scale for Depression

Description

Brenda D. Jamerson, PharmD

EVIDENCE-BASED MEDICINE

Effect of Bupropion SR on Specific Symptom Clusters of Depression: Analysis of the 31-Item Hamilton Rating Scale for Depression

Brenda D. Jamerson, PharmD, K. Ranga Rama Krishnan, MB, ChB, Jeremy Roberts, MS, Alok Krishen, MSc, MS, and Jack G. Modell, MD

Related products

Depression Rating Scales – A Doctor’s Guide

Generalized Anxiety Disorder: Raising the Expectations of Treatment

New Goals in the Treatment of Depression: Moving Toward Recovery By Michael E. Thase, MD, and Philip T. Ninan, MD

Switching to Duloxetine Remits Ziprasidone – Edward C. Lauterbach